Huma, a London and New York-based global healthcare AI company, has raised over $80 million in Series D funding, bringing its total funding to $300 million.
The company also announced the launch of its Huma Cloud Platform. The platform offers no-code configuration for regulated disease management tools across therapeutic areas, pre-built modules, device connectivity, cloud-agnostic hosting, APIs, integration capabilities, and the ability to host AI algorithms.
Investors
The round saw the participation of new and existing strategic and financial investors, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures, Leaps by Bayer, and others.
Huma Use of Funds
The company will use the funds to further accelerate its platform.
About Huma
Founded and led by Dan Vahdat, Huma specializes in digital health solutions. Huma is on a mission to accelerate the adoption of digital solutions in care and research. In 2023, Huma achieved the landmark milestone of becoming the first and only configurable, disease-agnostic FDA Class II, EU MDR Class IIb, and Saudi FDA Class C platform, enabling rapid, code-free configuration with the ability to host AI/ML models. Huma has powered projects in over 3,000 hospitals and clinics, engaged over 35 million individuals, and has 1.8 million active users across 70+ countries.
Funding Details
Company: Huma Therapeutics Limited
Raised: $80.0M
Round: Series D
Funding Month: July 2024
Investors: AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures and Leaps by Bayer
Company Website: https://www.huma.com/
Software Category: Healthcare AI
Source: https://www.huma.com/press-release-series-d-launches-huma-cloud-platform-genai